Univariable analysis of clinical characteristics potentially associated with time to death among 73 patients with lymphoma with LVEF assessment before and after receiving anthracycline
| Characteristic | Total (n=73) | Death (n=34) | 1-Year survival (SE) | 5-Year survival (SE) | p Value |
|---|---|---|---|---|---|
| AC-CMP | 0.02* | ||||
| Yes | 24 | 15 | 0.58 (0.10) | 0.38 (0.11) | |
| No | 49 | 19 | 0.80 (0.06) | 0.68 (0.07) | |
| Mediastinal radiation | 0.93 | ||||
| Yes | 8 | 4 | 0.88 (0.12) | 0.58 (0.19) | |
| No | 65 | 30 | 0.71 (0.06) | 0.59 (0.06) | |
| Age (years) | 0.07* | ||||
| <60 | 36 | 12 | 0.72 (0.07) | 0.69 (0.08) | |
| ≥60 | 37 | 22 | 0.73 (0.07) | 0.49 (0.09) | |
| Sex | 0.15* | ||||
| Female | 31 | 11 | 0.77 (0.08) | 0.63 (0.09) | |
| Male | 42 | 23 | 0.69 (0.07) | 0.55 (0.08) | |
| Race | 0.57 | ||||
| Black | 17 | 7 | 0.82 (0.09) | 0.70 (0.11) | |
| Caucasian | 51 | 25 | 0.71 (0.06) | 0.55 (0.07) | |
| Unknown | 5 | 2 | |||
| Smoking history | 0.67 | ||||
| Yes | 19 | 8 | 0.84 (0.08) | 0.71 (0.11) | |
| No | 47 | 20 | 0.72 (0.07) | 0.61 (0.07) | |
| Unknown | 7 | 6 | |||
| Hypertension§ | 0.81 | ||||
| Yes | 34 | 17 | 0.76 (0.07) | 0.61 (0.09) | |
| No | 38 | 16 | 0.71 (0.07) | 0.58 (0.09) | |
| Diabetes mellitus§ | 0.85 | ||||
| Yes | 9 | 4 | 0.78 (0.14) | 0.56 (0.17) | |
| No | 63 | 29 | 0.73 (0.06) | 0.60 (0.06) | |
| Hyperlipidaemia§ | 0.11* | ||||
| Yes | 16 | 4 | 0.88 (0.08) | 0.73 (0.12) | |
| No | 56 | 29 | 0.70 (0.06) | 0.55 (0.07) | |
| Coronary artery disease | 0.16* | ||||
| Yes | 12 | 8 | 0.75 (0.13) | 0.34 (0.15) | |
| No | 61 | 26 | 0.72 (0.06) | 0.63 (0.06) | |
*Variables that were included in multivariate regression model analysis.
§Total n=62, AC-CMP n=23.
AC-CMP, anthracycline-based chemotherapy-induced cardiomyopathy; LVEF, left ventricular ejection fraction.